Pfizer’s has recently announced the withdrawal of OXBRYTA ® (voxelotor) from all markets for the treatment of sickle disease. We’re closely monitoring the situation and working with partners to gather accurate information to share with our sickle cell community. At this time, we recommend that you talk to your healthcare provider if you have any concerns and before making any changes to your treatment. It’s important to get official updates through your provider, whether in person, a phone call or via MyChart.